Zoll gets US nod for paediatric AED (automated external defibrillator):
This article was originally published in Clinica
Executive Summary
Zoll Medical has gained US FDA 510(k) marketing clearance for a paediatric capability for its automated external defibrillator, AED Plus. This capability, for children up to eight years of age, includes voice prompts that tell rescuers what type of electrodes - adult or paediatric - are connected. This ensures that the proper electrodes and specific heart rhythm analysis algorithms for adults and children are used. Paediatric-specific energy levels are also incorporated in the device. "The [paediatric] capability allows us to approach more than 14,500 US public school districts and more than 27,000 private schools," said Richard Packer, the Chelmsford, Massachusetts firm's president and CEO.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.